September 18, 2026
Roche agrees $1bn deal with Dualitas for bispecific antibody research
Roche and Dualitas Therapeutics have entered a research collaboration and licence agreement that could reach a potential value of up to $1bn, aiming to discover and develop bispecific antibodies for immunology and inflammation (I&I) diseases.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







